- ISIN
- CH1125843347
- Sector
- Healthcare
- Industry
- Health Information Services
- IPO Date
- Jul 23, 2021
Highlights
- Market Cap
- $340.04M
- Enterprise Value
- $339.78M
- EPS (TTM)
- -$1.18
- Total Revenue (TTM)
- $81.18M
- Gross Profit (TTM)
- $54.62M
- EBITDA (TTM)
- -$66.11M
- Year Range
- $2.59 - $5.70
- Target Price
- $7.50
- ROA (TTM)
- -51.55%
- ROE (TTM)
- -177.15%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SOPH Performance Chart
SOPHiA GENETICS SA (SOPH) is up 2.4% since the beginning of the year. At $5 per share, SOPH is trading 16.1% below its 52-week high of $6.
Loading charts...
Returns By Period
SOPHiA GENETICS SA (SOPH) has returned 2.36% so far this year and 58.02% over the past 12 months.
SOPHiA GENETICS SA
- 1D
- -3.24%
- 1M
- -9.64%
- YTD
- 2.36%
- 6M
- -2.85%
- 1Y
- 58.02%
- 3Y*
- 2.57%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
SOPH Monthly Returns History
Based on dividend-adjusted daily data since Jul 23, 2021, SOPH's average daily return is +0.03%, while the average monthly return is -0.38%.
Historically, 37% of months were positive and 63% were negative. The best month was Mar 2023 with a return of +91.2%, while the worst month was Mar 2022 at -39.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SOPH closed higher 46% of trading days. The best single day was Mar 14, 2023 with a return of +37.5%, while the worst single day was Jan 18, 2022 at -19.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.42% | -14.29% | 10.00% | 5.45% | -3.26% | -5.35% | 2.36% | ||||||
| 2025 | 14.01% | 4.86% | -9.54% | -8.13% | -1.64% | 3.33% | 0.97% | 10.54% | 37.57% | 5.04% | -1.60% | -5.08% | 52.12% |
| 2024 | -2.55% | 8.93% | -1.40% | 3.45% | -2.16% | -8.22% | -3.93% | -12.73% | -4.95% | -1.92% | -4.75% | -9.97% | -34.82% |
| 2023 | 45.63% | -13.33% | 91.15% | -2.62% | -4.75% | -2.82% | -15.18% | -35.79% | 4.30% | 44.99% | 8.94% | 17.16% | 128.64% |
| 2022 | -17.02% | 9.40% | -39.61% | -16.82% | -34.68% | -13.81% | -4.70% | -4.64% | -20.06% | -16.35% | 5.00% | -10.82% | -85.39% |
| 2021 | -6.62% | 26.33% | -11.33% | -19.05% | -1.48% | 0.86% | -15.87% |
Benchmark Metrics
SOPHiA GENETICS SA has an annualized alpha of -6.31%, beta of 1.08, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since July 26, 2021.
- This stock participated in 155.31% of S&P 500 Index downside but only 19.50% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -6.31%
- Beta
- 1.08
- R²
- 0.05
- Upside Capture
- 19.50%
- Downside Capture
- 155.31%
Return for Risk
Risk / Return Rank
SOPH ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for SOPHiA GENETICS SA (SOPH) and compare them to S&P 500 Index.
| SOPH | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.87 | 2.24 | -1.37 |
Sortino ratioReturn per unit of downside risk | 1.66 | 3.07 | -1.41 |
Omega ratioGain probability vs. loss probability | 1.20 | 1.41 | -0.21 |
Calmar ratioReturn relative to maximum drawdown | 2.27 | 2.93 | -0.66 |
Martin ratioReturn relative to average drawdown | 5.30 | 13.52 | -8.22 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the SOPHiA GENETICS SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SOPHiA GENETICS SA was 91.35%, occurring on Nov 9, 2022. The portfolio has not yet recovered.
The current SOPHiA GENETICS SA drawdown is 75.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -91.35%Nov 2022 | 1y 2mo | — | 4y 9moSep 2021 - now |
2021 correction2021 | -10.71%Jul 2021 | 2d | 5d | 7dJul 2021 - Aug 2021 |
2021 pullback2021 | -7.38%Aug 2021 | 0s | 14d | 14dAug 2021 - Aug 2021 |
2021 pullback2021 | -2.69%Aug 2021 | 0s | 2d | 2dAug 2021 - Aug 2021 |
2021 pullback2021 | -2.06%Aug 2021 | 0s | 2d | 2dAug 2021 - Aug 2021 |
Drawdown Indicators
| SOPH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.35% | -56.78% | -34.57% |
Max Drawdown (1Y)Largest decline over 1 year | -25.72% | -9.10% | -16.62% |
Max Drawdown (3Y)Largest decline over 3 years | -52.67% | -18.90% | -33.77% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -75.82% | -0.74% | -75.08% |
Average DrawdownAverage peak-to-trough decline | -72.52% | -10.72% | -61.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.98% | 1.97% | +9.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of SOPHiA GENETICS SA over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how SOPHiA GENETICS SA is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SOPH relative to other companies in the Health Information Services industry. Currently, SOPH has a P/S ratio of 4.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SOPH in comparison with other companies in the Health Information Services industry. Currently, SOPH has a P/B value of 7.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SOPH
Add SOPHiA GENETICS SA to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SOPH